Market News & Trends
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers
Lirum Therapeutics, Inc. recently announced the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor…
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T Cell Modulators
GRI Bio, Inc. recently announced the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, Prevention and…
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
SciSparc Ltd. recently announced it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who…
Almirall & Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. recently announced the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall…
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML). TERN-701, the Company’s…
Cellares Unveils First cGMP-Compliant Cell Shuttle in its South San Francisco Center of Excellence
Cellares recently announced the completion of its first current Good Manufacturing Practice (cGMP)-compliant Cell Shuttle. The Cell Shuttle is an automated, ultra-high throughput, cell therapy…
Alcami Partners With Tanvex to Offer a Complete Solution for Biologics Developers
Alcami Corporation recently announced a new strategic partnership with Tanvex CDMO, a biologics developer offering pre-clinical to commercial biologic CDMO services. Through the collaboration, Alcami…
Moa to Develop Next-Gen Bioherbicides in New 10-Year Commercial Partnership With Croda
Deal will accelerate Moa’s development of next-generation bioherbicides, designed to tackle the global threat to food production from increasing weed resistance….
Ajinomoto Bio-Pharma Services Garners Six CDMO Leadership Awards, Further Establishing its Industry Excellence
Ajinomoto Bio-Pharma Services recently received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and…
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics….
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for First-in-Class NEK7 Directed Molecular Glue Degrader & NLRP3/IL-1β Pathway Inhibitor
Monte Rosa Therapeutics, Inc. recently announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102…
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
Immuneering Corporation recently announced the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead…
Acelyrin Announces Positive Top-line Results From Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
ACELYRIN, INC. recently announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16…
Athira Pharma Presents Clinical & Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases
Athira Pharma, Inc. presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD 2024 International Conference on Alzheimer’s and…
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children With Autism Spectrum Disorder
SciSparc Ltd. recently announced the first patient has been enrolled in the company's clinical trial assessing the efficacy and safety of SCI-210 for the treatment…
NodThera’s NLRP3 Inhibitor Reverses Neuroinflammation in Parkinson’s Disease Phase 1b/2a Trial
NodThera recently announced positive data from its Phase 1b/2a study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796,…
Genezen Announces Strategic Process Development & Manufacturing Partnership Agreement With Seattle Children’s Research Institute
Seattle Children’s Research Institute and Genezen have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia….
Hovione Partners With Dragonfly Technologies to Offer Micellar Chemistry Technology to Customers as a Sustainable Alternative to Conventional Chemical Processes
Hovione recently announced it has signed an agreement with Dragonfly Technologies, Inc. to gain access to its micellar technology for chemistry-in-water processes, developed by Prof. Bruce…
Adare Pharma Solutions to Expand Packaging & Warehousing Capabilities in Europe
Adare Pharma Solutions recently announced that work has begun to add packaging capabilities and further warehousing capacity at its….
Rentschler Biopharma Contributes to Nearly 25% of FDA-Approved Biopharmaceuticals in 2023
In 2023, the US FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a…
